News
23hon MSN
Jed Dorsheimer, William Blair analyst, joins 'The Exchange' to discuss Tesla's chip deal with Samsung and what it means for ...
Vertiv Holdings ( NYSE: VRT) on Monday was rated Outperform in new research coverage by analysts at investment firm William ...
19hon MSN
William Blair cheers Tesla-Samsung chip deal but keeps TSLA at Hold, citing auto margin woes and valuation concerns.
In addition, The Allstate Corporation (NYSE:ALL) is taking advantage of a far better auto loss environment and employing ...
Incyte posts strong Q2 results driven by Jakafi and Opzelura growth, lifts 2025 guidance despite challenges in future product development.
2h
Stocktwits on MSNSoFi’s ‘Disruptive’ Bank Model Gets A Wall Street Thumbs Up: Retail Chatter Explodes 380% In 24 HoursSoFi Technologies Inc. (SOFI) received a bullish endorsement from William Blair on Tuesday, following its second-quarter (Q2) ...
Explore more
(Reuters) -Sarepta Therapeutics shares surged more than 30% before the bell on Tuesday, as analysts said the resumption of ...
Executives at the laboratory companies said they expect the effects on testing services from the Republicans’ tax and ...
StockStory.org on MSN1h
5 Insightful Analyst Questions From CoStar’s Q2 Earnings CallCoStar’s second quarter saw solid execution, with revenue and non-GAAP earnings both surpassing Wall Street expectations, ...
Detailed price information for Booz Allen Hamilton Holding Corp (BAH-N) from The Globe and Mail including charting and trades.
Sarepta Therapeutics shares jumped over 36% on Tuesday after the company said it had received FDA approval to restart ...
In its own communique issued shortly after the FDA’s, Sarepta elaborated on the situation and confirmed a Roche statement to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results